VEGFA and myocardial infarction: While the use of intravenous bevacizumab is recognized to be associated with an increased risk of arterial and venous thromboembolic events [9], [10], it is controversial whether intravitreal anti-VEGF agents contribute to the development of arterial thromboembolic events, such as myocardial infarction and cerebrovascular accidents, common comorbidities leading to mortality in patients with ocular neovascular diseases [11], [12].